Phase I Trial: Quotient code QSC206231
| ISRCTN | ISRCTN30858255 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN30858255 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Integrated Research Application System (IRAS) | 1005504 |
| Protocol serial number | IRAS 1005504, Quotient code: QSC206231 |
| Sponsor | Nanomerics Ltd |
| Funder | Nanomerics Ltd |
- Submission date
- 12/11/2024
- Registration date
- 22/11/2024
- Last edited
- 10/12/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Deferred
- Condition category
- Other
Plain English summary of protocol
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Contact information
Principal investigator
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
NG11 6JS
United Kingdom
| Phone | +44 (0)330 303 1000 |
|---|---|
| recruitment@weneedyou.co.uk |
Public
Nanomerics Ltd
2 London Wall Place
6th Floor
London
EC2Y 5AU
United Kingdom
| Phone | +44 (0)20 3397 2183 |
|---|---|
| andreas.g.schatzlein@nanomerics.com |
Scientific
Nanomerics Ltd
2 London Wall Place
6th Floor
London
EC2Y 5AU
United Kingdom
| Phone | +44 20 3397 2183 |
|---|---|
| andreas.g.schatzlein@nanomerics.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Single-centre randomized study to assess safety, tolerability and pharmacokinetics in 10 healthy volunteers |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Phase I Trial: Quotient code QSC206231 |
| Study objectives | The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Ethics approval(s) |
Submitted 24/07/2024, HSC REC B (ORECNI, Lissue Industrial Estate West, 5 Rathdown Walk, Lisburn, Co. Antrim, BT28 2RF, United Kingdom; +44 (0)2895361400; recb@hscni.net), ref: 24/NI/0093 |
| Health condition(s) or problem(s) studied | The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Intervention | The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Intervention type | Drug |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Primary outcome measure(s) |
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Key secondary outcome measure(s) |
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Completion date | 07/01/2025 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 10 |
| Key inclusion criteria | Healthy volunteer |
| Key exclusion criteria | The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Date of first enrolment | 25/11/2024 |
| Date of final enrolment | 07/01/2025 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Ruddington Fields
Ruddington
Nottingham
NG11 6JS
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan | The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
10/12/2024: HRA confirmed the deferral.
12/11/2024: Study's existence confirmed by the MHRA.
